Johnson & Johnson raised its full-year guidance and absorbed $330 million in talc litigation charges in the first quarter, while Pfizer bet roughly $7 billion on GLP-1 obesity assets to offset collapsing COVID revenue. JNJ posted $24.062 billion in revenue, up 9.9%, with DARZALEX clearing $3.964 billion, and lifted its outlook to $100.8 billion in revenue and $11.55 in adjusted EPS. Pfizer delivered $14.451 billion in revenue, up 5.4%, but saw Comirnaty drop 59% and Paxlovid drop 62%, while CEO Albert Bourla said the company is positioned to lead in oncology and obesity. JNJ's 64-year dividend streak, 46% payout ratio, and $21 billion free cash flow target make the talc litigation noise a buying opportunity, according to the analysis.
Johnson & JohnsonRaised full-year guidance and revenue up 9.9%, with strong DARZALEX sales and $21B free cash flow target.
Pfizer IncRevenue up 5.4% and CEO positions company to lead in oncology and obesity, despite COVID product declines.
NVIDIA Corporation